# Daraxonrasib extended survival in metastatic pancreatic cancer in phase III RASolute-302 trial

- Published: 2026-11-14 21:23 UTC
- Section: Life & Health › Medicine
- Tags: daraxonrasib, metastatic pancreatic cancer, RAS(ON) inhibitor, RASolute-302, phase III trial, median overall survival, progression-free survival, pan-RAS inhibitor
- URL: https://realtech.media/news/rt-e6376896417788d97b89d2c6_daraxonrasib_extended_survival/

**In a phase III trial of 500 patients, oral daraxonrasib gave a median survival of 13.2 months versus 6.7 months with chemotherapy after prior treatment.**

![Daraxonrasib extended survival in metastatic pancreatic cancer in phase III RASolute-302 trial](https://realtech.media/media/2026/11/cba1028bc4be921b.jpg)
*Sciences et Avenir*

Results of the phase III RASolute-302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma were published in the New England Journal of Medicine [1]. They were presented on 31 May 2026 at the ASCO congress in Chicago. The trial compared the oral drug with standard chemotherapy and included 500 patients worldwide.

Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active, guanosine triphosphate-bound state of mutant and wild-type RAS [1]. RAS mutations are present in more than 90% of pancreatic tumors [1]. The drug is taken as tablets once a day at home, while the reference chemotherapy is given by infusion, most often in a hospital.

## Survival and response

Median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Median progression-free survival in the G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy. In the overall population it was 7.2 months and 3.6 months, respectively [1]. The hazard ratios were 0.45 and 0.49 (P<0.001 for both comparisons) [1].

An objective response, a significant reduction in tumor size, was recorded in 31.6% of patients on daraxonrasib and in 11.2% on chemotherapy. Time to deterioration of quality of life was 5.7 months versus 2.6 months. Time to worsening of pain was 9.2 months versus 3.8 months.

## Safety and limits

Adverse events after the start of treatment were reported in all patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group [1]. Events of grade 3 or higher occurred in 61.8% and 69.6%, respectively. Treatment-related adverse events that led to discontinuation occurred in 1.2% of patients on daraxonrasib and in 11.2% on chemotherapy [1].

According to Pascal Hammel, head of digestive and medical oncology at Paul-Brousse hospital, the main adverse event was a skin rash, seen in more than 85% of patients. He also noted effects in patients whose tumors had no KRAS mutation. Only 16 such patients took part, so these results and the tolerability in this group need confirmation.

## Sources

1. [New England Journal of Medicine](https://doi.org/10.1056/NEJMoa2605555)
2. [Sciences et Avenir](https://www.sciencesetavenir.fr/sante/cancer-du-pancreas-la-percee-du-daraxonrasib_195859)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-e6376896417788d97b89d2c6_daraxonrasib_extended_survival/